LINC02154 Promotes Esophageal Squamous Cell Carcinoma Progression via the PI3K–AKT–mTOR Signaling Pathway by Interacting With IGF2BP2
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.23903 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Mingyuan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, RNA, Long Noncoding, Proto-Oncogene Proteins c-akt, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: This research was supported by the National Natural Science Foundation of China [grant numbers 82103324, 82172351, and 82472367] and the Natural Science Founda…, National Natural Science Foundation of China.
Abstract (Originalsprache)
As important types of noncoding RNAs, long noncoding RNAs (lncRNAs) have been found to be involved in the progression of various cancers. Accumulating evidence indicates that LINC02154 plays a critical role in cancer progression, but the underlying mechanisms regulating esophageal squamous cell carcinoma (ESCC) remain unclear. Here, we found that LINC02154 is significantly upregulated in ESCC cell lines and ESCC tissues. LINC02154 knockdown significantly inhibited the proliferation and migration of ESCC cells in vitro and suppressed the progression of ESCC in vivo. Mechanistically, LINC02154 can bind to IGF2BP2 and activate the PI3K–AKT–mTOR signaling pathway. High expression of LINC02154 is positively correlated with poor prognosis in ESCC patients. In conclusion, LINC02154 functions as an oncogenic factor to facilitate ESCC progression through the IG2BP2–PI3K–AKT–mTOR pathway and has the potential to be a promising diagnostic marker and therapeutic target for ESCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Key Clinical Laboratory of Henan province, Zhengzhou, China.
- Thoracic Department, Anyang Tumor Hospital, Henan Key Medical Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang, China.
ORCID-Profile: Mingyuan Zhang
Förderung
- This research was supported by the National Natural Science Foundation of China [grant numbers 82103324, 82172351, and 82472367] and the Natural Science Founda…
- National Natural Science Foundation of China
Zitieren
APA
Zhang, M., Zhang, C., Zhou, F., Yang, R., Feng, Y., Ji, Y., Ren, H., & Ming, L. (2025). LINC02154 Promotes Esophageal Squamous Cell Carcinoma Progression via the PI3K–AKT–mTOR Signaling Pathway by Interacting With IGF2BP2. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23903
Vancouver
Zhang M, Zhang C, Zhou F, Yang R, Feng Y, Ji Y, et al. LINC02154 Promotes Esophageal Squamous Cell Carcinoma Progression via the PI3K–AKT–mTOR Signaling Pathway by Interacting With IGF2BP2. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23903
BibTeX
@article{Zhang2025,
author = {Zhang, Mingyuan and Zhang, Cai and Zhou, Fuyou and Yang, Ruotong and Feng, Yang and Ji, Yangyang and Ren, Huijun and Ming, Liang},
title = {LINC02154 Promotes Esophageal Squamous Cell Carcinoma Progression via the PI3K–AKT–mTOR Signaling Pathway by Interacting With IGF2BP2},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.23903}
}
EUVIMED